CANCER&RESEARCH&UK&& & IAN&WALKER&PHD,&MBA& DIRECTOR,&STRATEGIC&PARTNERSHIPS&

Transcription

1 CANCER&RESEARCH&UK&& & IAN&WALKER&PHD,&MBA& DIRECTOR,&STRATEGIC&PARTNERSHIPS&

2 An&introduc>on&to&CRUK&

3 Cancer&Research&UK& Who&we&are& The$largest$fundraising$medical$research$charity$in$the$world.$ The$largest$funder$of$cancer$research$in$Europe.$ The$second$largest$$global$funder$of$cancer$research$a9er$the$US$ government.$ What&we&spend& & We$spent$ 338m$on$research$in$2012/13$ We$are$almost$exclusively$funded$through$public$donaFons$ The$money$we$raise$is$spent$on$$ Research$ InformaFon$ Advocacy$and$public$policy$

4 A&UKEwide&network&with&unique&capabili>es& 5$coreEfunded&ins>tutes& 15$Cancer&Centres& 4&Cancer&Imaging&Centres& 18&ECMCs& 7&Clinical&Trials&Units& Our&Drug&Development& Office$

5 Our&Strategy&

6 Cancer&Research&UK s&ambi>on& Over the last 40 years, cancer survival in the UK has doubled. In the 1970s just a quarter of people survived. Today that figure is half. Our ambition is to accelerate progress an see three-quarters of patients surviving the disease within the next 20 years. 6$

7 We&intend&to&achieve&our&ambi>on&through&a&substan>al& increase&in&research&spend&in&the&following&areas& Early& diagnosis& research$ Basic& understanding& of&cancer$ Therapeu>c& innova>on$ Cancers of substantial unmet need Cancer& preven>on$ Precision& medicine$ To help deliver these priorities, we will: Launch new funding schemes Invest in our translational network Encourage collaborative approaches Develop the best researchers

8 Greater&understanding&of&interEpa>ent&heterogeneity&has& highlighted&its&impact&on&prognosis&&&treatment&response& Redefining breast cancer: the METABRIC study Mutational spectrum in Lung Adenocarcinoma Extremely poor 5 Poor 2 10 *& Intermediate Good Patient outlook Cluster 10$disFnct$clusters$with$varying$clinical$ outcome$ The % distribution of clinically relevant driver mutations identified to date in individuals with lung adenocarcinoma. (TGCA, Nature, 548, vol 511 (2014)) NSCLC&pa>ent&group& EGFR$mutant*$ EGFR$WT$ PFS&gain&Erlo>nib&vs&chemo& 5.2$mths$ O1.9$mths$ * Poor 5-year outcome; good long-term outcome if alive at 5 years * EGFRexon 19 deletions or exon 21 (L858R) substitution mutations

9 Significant&technology&advances,&have&accelerated&the& progress&in&precision&medicine& The dramatic decrease in the cost of Whole Genome Sequencing has outpaced Moore s Law 1 $100,000k$ Sanger&sequencing& Next&genera>on&sequencing& $10,000k$ Moore s law $1,000k$ $100k$ Current cost of NGS whole genome sequencing is c. $4,000 $10k$ $1k$ SepO01$ MayO02$ JanO03$ SepO03$ MayO04$ JanO05$ SepO05$ MayO06$ JanO07$ SepO07$ MayO08$ JanO09$ SepO09$ MayO10$ JanO11$ SepO11$ MayO12$ JanO13$ SepO13$ 1: National Human Genome Research Institute, Data from the NHGRI Genome Sequencing Program (GSP)

10 Response&to&crizo>nib&in&ALK+&adenocarcinoma& July 2012 baseline Sept 2012 duration of crizotinib tx: 1 month Thanks to Dr Sanjay Popat (RMH), for providing this slide

11 CRUK& STRATIFIED& MEDICINE&&2&

12 A&collabora>ve&model& The programme represents a combined investment of over 20M by the funding Partners. Up to 14 drugs could be involved over the course of the programme.

13 Biomarker A : Drug A Biomarker B : Drug B Biomarker C : Drug C Biomarker D : Drug D Biomarker E: Drug E Biomarker F : Drug F Biomarker etc Drug etc Pre-screening NGS sequencing MATRIX Lung Study Upto$2000$NSCLC$paFents$screened$per$year$ NaFonal$screening$to$naFonal$trial$ 28$gene$mulFplexed$NGS$panel;$detects$mutaFons,$ delefons,$cnv$and$dna$rearrangement$ UFlising$DNA$from$rouFne$FFPE$biopsies$ 6$drugs,$14$straFfied$arms$to$begin$with$ Phase$2a$signal$finding$study$ Rolling$protocol,$capable$of$incorporaFng$new$arms$ Sponsored$by$CRCTU$at$Birmingham$ PI$Professor$Gary$Middleton$ Recruit$across$18$ECMC$centres$

14 SMP2:&An&Alterna>ve&Approach& DiagnosFc$ biopsy$ Current*pathway* NHS$single$ gene$test$ NHS$ Treatment$ Consent$for$ study$$ Single$gene$ test$for$study$$ EGFR$ If$test$ negafve$ Recruit$if$ posifve$ e.g.$braf$ Collabora've** pre,screening* Generic$ consent$ Panel$test$$ e.g.$ngs$ NHS$Treatment$ Recruit$to$drug$1$ Recruit$to$drug$2$ Recruit$to$drug$3$ Recruit$to$drug$n$ Shared$cost$ Quicker$ Easier$for$ pafents$ Fewer$ rebiopsies$ Includes$ rare$ mutafons$

15 Summary& SMP2$will$change$the$way$we$develop$straFfied$medicines$ within$the$uk$and$provide$greater$opfons$for$pafents$with$ lung$cancer.$$ The$programme$will$be$a$NaFonal$effort$across$the$enFre$ ECMC$network$and$beyond.$ A$model$uFlising$shared$preOscreening$provides$benefits$for$ pafents,$sponsors$and$pharmaceufcal$companies$

16 END& cruk.org&